Howard Grosfield, Group President of U.S. Consumer Services at American Express Co, filed a Form 4 on November 3, 2026, disclosing the vesting of 17,465 employee stock options on October 31, 2026.
Anna Marrs, Group President of Global Merchant and Network Services at American Express Co (NYSE:AXP), filed a Form 4 on November 3, 2026, disclosing the exercise of employee stock options and the sale of common stock on November 2, 2026.
American Express Chairman and CEO Stephen J. Squeri was reported as acquiring 74,850 employee stock options in a beneficial ownership statement filed with the SEC on November 3, 2026, reflecting the vesting of a portion of a 2022 performance-based award.
American Express Co Chief Colleague Experience Officer Monique Herena filed a Form 4 on November 3, 2026, disclosing the acquisition of 17,465 employee stock options in American Express common stock on October 31, 2026.
American Express Co Chief Legal Officer Laureen Seeger filed a Form 4 on November 3, 2026, disclosing the exercise of employee stock options and the same-day sale of 69,860 shares of common stock on November 2, 2026.
Debbra L. Schoneman, President of Piper Sandler Companies (NYSE:PIPR), filed a Form 4 on November 3, 2026, reporting the exercise of employee stock options and a same-day sale of 39,708 shares of common stock on November 2, 2026.
Director Joseph A. Schottenstein filed a Form 4 with the SEC on November 3, 2026, disclosing an acquisition of Class A Common Shares of Designer Brands Inc. on October 30, 2026.
A Form 4 filed on November 3, 2026 discloses that Imran Khan, Chief Executive Officer and Director of Proem Acquisition Corp. I (NASDAQ:PAAC), reported an open-market purchase of 2,000 ordinary shares on November 2, 2026 at a price of $10.30 per share.
Independence Realty Trust, Inc. filed a Form 425 on November 3, 2026, disclosing the transcript of its Third Quarter 2026 Earnings Conference Call, which covered standalone financial results and provided an update on the pending merger with Centerspace.
Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (NASDAQ:BBIO), filed a Form 4 on November 3, 2026, disclosing the sale of 2,000 shares of common stock on October 30, 2026.